Barinthus Biotherapeutics plc
BRNS
$0.73
$0.011.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -52.18% | -100.20% | -25.90% | -88.71% | 1,564.48% |
| Gross Profit | -229.18% | 100.20% | 25.90% | 88.71% | 442.09% |
| SG&A Expenses | -62.08% | 113.64% | 103.23% | -124.73% | 1,062.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 97.75% | -480.00% | -- | -- |
| Total Operating Expenses | -57.97% | 24.95% | 24.69% | -86.30% | 60.65% |
| Operating Income | -9.25% | -24.95% | -24.69% | 86.30% | 38.19% |
| Income Before Tax | -80.05% | -24.78% | -26.50% | -13.68% | 44.73% |
| Income Tax Expenses | -2,266.67% | -257.14% | 40.54% | 100.37% | 99.50% |
| Earnings from Continuing Operations | -79.25% | -24.69% | -26.66% | -19.09% | 42.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -66.67% | -83.33% | -67.74% | 1,800.00% | -60.53% |
| Net Income | -79.52% | -24.77% | -26.85% | -18.78% | 42.34% |
| EBIT | -9.25% | -24.95% | -24.69% | 86.30% | 38.19% |
| EBITDA | -16.58% | -22.78% | -21.86% | 89.17% | 39.98% |
| EPS Basic | -74.05% | -20.73% | -22.15% | -14.12% | 43.65% |
| Normalized Basic EPS | -11.82% | -20.89% | -22.39% | 90.09% | 42.92% |
| EPS Diluted | -71.43% | -20.73% | -22.50% | -13.62% | 43.24% |
| Normalized Diluted EPS | -11.82% | -20.89% | -22.39% | 90.09% | 42.92% |
| Average Basic Shares Outstanding | 3.15% | 3.34% | 3.85% | 4.07% | 2.30% |
| Average Diluted Shares Outstanding | 3.15% | 3.34% | 3.85% | 4.07% | 2.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |